Characterization of Potential CD138 Negative Myeloma "stem Cells"

Overview

Journal Haematologica

Specialty Hematology

Date 2012 Jun 6

PMID 22665530

Citations 5

Authors

Jacob H Christensen

Pia V Jensen

Ida B Kristensen

Niels Abildgaard

Marianne Lodahl

Thomas Rasmussen

Affiliations

Soon will be listed here.

Citing Articles

Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.

Leivas A, Risueno R, Guzman A, Sanchez-Vega L, Perez M, Megias D Cancer Immunol Immunother. 2021; 70(10):2911-2924.

PMID: 33693963 PMC: 8423695. DOI: 10.1007/s00262-021-02901-y.

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen H, Bogsted M, Schmitz A, Bodker J, El-Galaly T, Johansen P Haematologica. 2016; 101(12):1451-1459.

PMID: 27903712 PMC: 5479618. DOI: 10.3324/haematol.2015.138826.

Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.

Oldaker T, Wallace P, Barnett D Cytometry B Clin Cytom. 2015; 90(1):40-6.

PMID: 26201282 PMC: 5404813. DOI: 10.1002/cyto.b.21276.

Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.

Paino T, Sarasquete M, Paiva B, Krzeminski P, San-Segundo L, Corchete L PLoS One. 2014; 9(3):e92378.

PMID: 24658332 PMC: 3962421. DOI: 10.1371/journal.pone.0092378.

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Kassambara A, Schoenhals M, Moreaux J, Veyrune J, Reme T, Goldschmidt H PLoS One. 2013; 8(4):e62752.

PMID: 23646139 PMC: 3640027. DOI: 10.1371/journal.pone.0062752.

References

Matsui W, Wang Q, Barber J, Brennan S, Smith B, Borrello I . Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008; 68(1):190-7. PMC: 2603142. DOI: 10.1158/0008-5472.CAN-07-3096. View

Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E . Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood. 2007; 109(11):4914-23. PMC: 2268882. DOI: 10.1182/blood-2006-08-043232. View

Matsui W, Huff C, Wang Q, Malehorn M, Barber J, Tanhehco Y . Characterization of clonogenic multiple myeloma cells. Blood. 2003; 103(6):2332-6. PMC: 3311914. DOI: 10.1182/blood-2003-09-3064. View

Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi J . The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998; 100(4):637-46. DOI: 10.1046/j.1365-2141.1998.00623.x. View

Yang Y, MacLeod V, Miao H, Theus A, Zhan F, Shaughnessy Jr J . Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem. 2007; 282(18):13326-33. DOI: 10.1074/jbc.M611259200. View